Add to ORKG<p>The analysis of the performed study has established that zoledronic acid is an effective agent in multimodality therapy for locally advanced prostate cancer (PC) and allows long-term stabilization of bone tissue. In addition, there is evidence for the efficacy of zoledronic acid in preventing bone metastases (BM) and increasing the time to the first BM. The currently accumulated experience with zoledronic acid used in PC permits one to consider its use as standard concomitant therapy.</p
Item does not contain fulltextAnticancer therapies have traditionally been targeted directly against...
Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probabl...
PURPOSE: The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metasta...
Background Patients with high-risk localised prostate cancer (PCa) are at risk of developing bone me...
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion ev...
Patients with prostate cancer are at risk for skeletal complications resulting from treatment-induce...
<p>In the metastatic patterns of the cancer, the tumor foci are located more frequently in the tubul...
Bone metastases are a common feature of a variety of solid tumors and are associated with substantia...
Background: Patients with high-risk localised prostate cancer (PCa) are at risk of developing bone m...
Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastati...
Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for impro...
Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Mo...
Bone metastases alone or in combination with androgen deprivation therapy-related bone loss places p...
This subset analysis examined the therapeutic effect of zoledronic acid on patients with renal cell ...
I in renal cancer patients probably related to survival increase. There are few data in literature a...
Item does not contain fulltextAnticancer therapies have traditionally been targeted directly against...
Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probabl...
PURPOSE: The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metasta...
Background Patients with high-risk localised prostate cancer (PCa) are at risk of developing bone me...
In a placebo-controlled randomized clinical trial, zoledronic acid (4 mg via a 15-minute infusion ev...
Patients with prostate cancer are at risk for skeletal complications resulting from treatment-induce...
<p>In the metastatic patterns of the cancer, the tumor foci are located more frequently in the tubul...
Bone metastases are a common feature of a variety of solid tumors and are associated with substantia...
Background: Patients with high-risk localised prostate cancer (PCa) are at risk of developing bone m...
Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastati...
Objectives: A multi-centered observational study evaluated the efficacy of zoledronic acid for impro...
Bisphosphonate therapy has become a standard of therapy for patients with malignant bone disease. Mo...
Bone metastases alone or in combination with androgen deprivation therapy-related bone loss places p...
This subset analysis examined the therapeutic effect of zoledronic acid on patients with renal cell ...
I in renal cancer patients probably related to survival increase. There are few data in literature a...
Item does not contain fulltextAnticancer therapies have traditionally been targeted directly against...
Introduction. Bone metastases are an emerging clinical problem in colorectal cancer patients probabl...
PURPOSE: The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metasta...